Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer

University Hospital, Strasbourg, France100 enrolled

Overview

The aim of this retrospective study is to evaluate the value of pre-treatment and post-treatment multimodality MRI study, including quantitative evaluation of background parenchymal enhancement, for response prediction and evaluation. This study will include 100 patients treated in a single institution between 2011 and 2016

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients * Patients with breast cancer treated with neoadjuvant chemotherapy * Patients with pre- and post-chemotherapy MRI * Patients who have given their agreement to use their data for research purposes. Exclusion Criteria: \- Refusal to participate in the study

Locations (1)

Service Imagerie 1

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Presence or absence of of pathologic enhancement of breast by MRI

This work concerns 110 patients treated with neoadjuvant chemotherapy for breast cancer and having received a breast MRI in pre and post-chemiotherapy at the Hautepierre Hospital.

Time frame: 1 hour after the realization of the MRI

Central Contacts

Sébastien MOLIERE, MD

CONTACT

33 3 88 12 78 65 sebastien.moliere@chru-strasbourg.fr

Marie-Noëlle ROEDLICH, MD

CONTACT

33 3 88 12 78 65 marie-noelle.roedlich@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.